<DOC>
	<DOC>NCT01132495</DOC>
	<brief_summary>The overall purpose of the FAME II trial is to compare the clinical outcomes, safety and cost-effectiveness of FFR-guided PCI plus optimal medical treatment (OMT) versus OMT alone in patients with stable coronary artery disease.</brief_summary>
	<brief_title>FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT</brief_title>
	<detailed_description>Prospective, multi-center, multi-national, multi-continental, randomized clinical trial.</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1. Patients with stable angina or, stabilized angina pectoris or, atypical chest pain or no chest pain but with documented silent ischemia 2. at least one stenosis is present of at least 50% in one major native epicardial coronary artery and supplying viable myocardium 3. Eligible for PCI 4. Signed written informed consent 1. Patients in whom the preferred treatment is CABG 2. Patients with left main coronary artery disease requiring revascularization 3. Patients with a recent STEMI or NonSTEMI 4. Prior CABG 5. Contraindication to dual antiplatelet therapy 6. LVEF &lt; 30% 7. Severe LV hypertrophy 8. Planned need for concomitant cardiac surgery 9. Extremely tortuous or calcified coronary arteries precluding FFR measurements 10. A life expectancy of less than 2 years 11. Age under 21</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Stable angina</keyword>
	<keyword>angina pectoris</keyword>
	<keyword>PCI</keyword>
	<keyword>FAME</keyword>
	<keyword>FAME II</keyword>
	<keyword>FFR</keyword>
	<keyword>Fractional Flow Reserve</keyword>
	<keyword>Pressure wire</keyword>
</DOC>